Vivan's Personal Discovery ProcessTM replicates a patient's genetic profile and screens thousands of drug cocktails – our Drug Discovery/Development Process enables screening of investigational drugs & combinations.
We have seen success in the hardest to treat patients.
Patient case study: 45% reduction in size of target lesions and 11-month extension of life.
• End stage 53 year old colorectal cancer patient with multiple failed treatments.
• Tumour sequencing and analysis identified recurrent (KRAS, APC, TP53) and new (CDH1, FBXW7, etc) CRC mutations. • 9 genetic alterations were engineered into Vivan fruit flies.
• Drug screening identified a novel drug combination of a cancer drug and non cancer drug, making.
treatment less toxic: MEKi + bisphosphonate.
lP developed at Mt Sinai Medical Center, NY & exclusively licensed.
plicate full cancer pathology in a living organism (in vivo).
All mutations identified in a human tumour can be engineered in a fly (up to20 mutations).
Low cost and high speed (short study times) enable large numbers of animals pertest, generating more robust, quantitative whole animal data.
Robotics and automation enables high drug throughput.
Core IP developed through 8 years of R&D by Mount Sinai ($10m grant from NIH).